...
首页> 外文期刊>Cancer research: The official organ of the American Association for Cancer Research, Inc >TP53 Silencing Bypasses Growth Arrest of BRAF(V600E)-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis
【24h】

TP53 Silencing Bypasses Growth Arrest of BRAF(V600E)-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis

机译:TP53沉默绕过BRAF(V600E)诱导的肺肿瘤发生的两开关模型中的肺癌细胞的生长停滞。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Lung carcinogenesis is a multistep process in which normal lung epithelial cells are converted to cancer cells through the sequential acquisition of multiple genetic or epigenetic events. Despite the utility of current genetically engineered mouse (GEM) models of lung cancer, most do not allow temporal dissociation of the cardinal events involved in lung tumor initiation and cancer progression. Here we describe a novel two-switch GEM model for BRAFV(600E)-induced lung carcinogenesis allowing temporal dissociation of these processes. In mice carrying a Flp recombinase activated allele of Braf (Braf(FA)) in conjunction with Cre-regulated alleles of Trp53, Cdkn2a, or c-MYC, we demonstrate that secondary genetic events can promote bypass of the senescence-like proliferative arrest displayed by BRAFV(600E)-induced lung adenomas, leading to malignant progression. Moreover, restoring or activating TP53 in cultured BRAFV(600E)/TP53Null or BRAFV(600E)/ INK4A-ARFNull lung cancer cells triggered a G1 cell-cycle arrest regardless of p19ARF status. Perhaps surprisingly, neither senescence nor apoptosis was observed upon TP53 restoration. Our results establish a central function for the TP53 pathway in restricting lung cancer development, highlighting the mechanisms that limit malignant progression of BRAFV(600E)-initiated tumors. (C) 2015 AACR.
机译:肺癌发生是一个多步骤过程,其中正常肺上皮细胞通过顺序获取多个遗传或表观遗传事件而转化为癌细胞。尽管当前的肺癌的基因工程小鼠(GEM)模型有用,但大多数都不允许与肺癌起始和癌症进展有关的主要事件在时间上分离。在这里我们描述了BRAFV(600E)诱导肺致癌作用的新型两开关GEM模型,可暂时分离这些过程。在携带Flp重组酶激活的Braf(Braf(FA))等位基因与Cre调控的Trp53,Cdkn2a或c-MYC等位基因的小鼠中,我们证明了次级遗传事件可以促进所显示的衰老样增殖性停滞的旁路由BRAFV(600E)诱导的肺腺瘤,导致恶性进展。此外,在培养的BRAFV(600E)/ TP53Null或BRAFV(600E)/ INK4A-ARFNull肺癌细胞中恢复或激活TP53均可触发G1细胞周期停滞,而与p19ARF的状态无关。也许令人惊讶的是,TP53恢复时未观察到衰老或凋亡。我们的结果为限制肺癌的发展建立了TP53通路的核心功能,强调了限制BRAFV(600E)引发的肿瘤恶性进展的机制。 (C)2015 AACR。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号